Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study.

@article{Valantin2012LongtermEO,
  title={Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study.},
  author={M A Valantin and Sidonie Lambert-Niclot and Philippe Flandre and Laurence Morand-Joubert and Andr{\'e} Cabi{\'e} and J L Meynard and Diane Ponscarme and Fa{\"i}za Ajana and Laurence Slama and Ang{\'e}lique Curjol and Lise Cuzin and Luminita Schneider and Anne Marie Taburet and A. Marcelin and Christine Katlama},
  journal={The Journal of antimicrobial chemotherapy},
  year={2012},
  volume={67 3},
  pages={691-5}
}
OBJECTIVES Long-term results at week 96 are needed to evaluate the capacity of the darunavir/ritonavir monotherapy strategy to maintain a sustained control of the HIV-1 viral load. METHODS MONOI is a prospective, open-label, non-inferiority, randomized, 96 week trial comparing darunavir/ritonavir monotherapy versus a darunavir/ritonavir triple-therapy strategy to maintain HIV-1 viral load suppression in HIV-1-infected patients. CLINICAL TRIAL REGISTRATION NCT00412551. RESULTS From 225… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.
25 Citations
10 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 10 references

Similar Papers

Loading similar papers…